Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2020

View Archived Issues

Distinguishing real from backseat drivers

Blocking bad bone

Discovery of macrocyclic ASK1 inhibitors with potential applications in neurodegenerative diseases

SLC25A1 plays a role in the pathogenesis of fatty liver disease and is a druggable target

Arbutus discontinues development of its first generation oral HBV RNA-destabilizer

Myovant reports positive one-year data from phase III LIBERTY extension study

Rezolute initiates phase IIb study of RZ-358 in congenital hyperinsulinism

Promising preclinical data presented for AdC-gDE765dt vaccine

Taiho Pharmaceutical presents phase I data for TAS-0313 cancer peptide vaccine

Initial phase I data for binimetinib plus pembrolizumab in TNBC

First data presented for UV-1 cancer vaccine combined with ipilimumab in malignant melanoma

Newly identified HIV broadly neutralizing antibody is hard to escape

Intellia presents new results for its cell therapy development programs

Phenex Pharmaceuticals AG patents new AhR antagonists

BeiGene discloses adenosine A2A receptor antagonists

Sestrins protect against muscle wasting by coordinating anabolic and catabolic pathways

Merck KGaA presents PSMB8 inhibitors

Roche describes new oligonucleotides targeting Spi1 proto-oncogene

Intrexon patents ROR1-targeting CARs

Primary objective met in phase II study of TTP-399 in type 1 diabetes

Phase III trial of troriluzole in generalized anxiety disorder misses primary endpoint

FDA accepts IND for phase I/II study of Inovio's INO-3107 for recurrent respiratory papillomatosis

Health Canada clears Bold to begin phase Ib study of BOLD-100 in gastrointestinal cancers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...